Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
NCT07848243
Summary
\[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors
Eligibility
Inclusion Criteria: 1. Age \>18 years old, ECOG score 0 or 1; 2. subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors; 3. There was at least one measurable target lesion according to RECIST1.1 criteria; 4. Predicted survival time ≥12 weeks; 5. Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements; 6. Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives/pills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period; 7. Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good. Exclusion Criteria: 1. Severe abnormal liver and kidney function. 2. Pre-pregnancy, pregnant and lactating women. 3. Unable to lie flat for half an hour. 4. Refusal to be a clinical investigator. 5. Claustrophobia or other mental illness. 6. Known allergy to the investigational drug or its excipients in the study treatment; Other circumstances considered by the investigator to be inappropriate for trial participation.
Conditions7
Interventions2
Related trials
- 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients — Peking Union Medical College Hospital
- A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma — Peking University First Hospital
- CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Hua Zhu
- CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Peking University Cancer Hospital & Institute
- Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging — Peking University Cancer Hospital & Institute
- Lung Nodule Detection Using Ultra-long FOV PET/CT — University Medical Center Groningen
- Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma — Peking University Cancer Hospital & Institute
- Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization — Hua Zhu
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07848243